The United Kingdom and the United States have hammered out a major bilateral deal that will ensure no levies on UK pharmaceutical shipments going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to boost expenditure on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key exports will stay at nothing for a timeframe of 36 months.
This agreement is in response to earlier threats to dramatically increase duties on patented drug products, with figures discussed as high as 100%.
"This agreement between the Britain bolsters the global environment for new treatments and introduces much-needed balance to transatlantic pharmaceutical trade," a statement noted.
Commercial Significance
Medicines are one of the the United Kingdom's most significant goods shipped to the United States, which is clearly the largest destination for large UK drugmakers.
Statistics indicate that in the 12 months prior to September, the UK shipped medicines valued at over eleven billion pounds to the US. This value represented nearly one-fifth of all goods exports in that span.
"This deal protects jobs, stimulates investment and paves the way for the UK to become a global hub for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The agreement entails several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to double total public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at 15%. Previously, rebates exceeded twenty percent.
Recent Tensions
This agreement follows a protracted dispute between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by claims that American customers were paying a premium for the identical medicines than people in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
